Reuters Creates The Outpartnering Registry

Thomson Reuters announced recently that it has launched The Outpartnering Registry, an innovative resource designed to change the way biotechnology, pharmaceutical and academic organizations find partnering opportunities around the world.

The Outpartnering Registry is available free to all organizations with drugs in development. It enables authorized users to share essential information about their company and drug pipeline with potential partners. Ninety percent of the world's top 50 pharmaceutical companies will have access to information in the registry via Thomson Pharma Partnering, the leading source of pipeline intelligence.

The Outpartnering Registry allows organizations to:

  • Indicate which of their programs and drugs are available for partnering and, optionally, what type of partnership they are seeking in which regions of the world.
  • Add and update partnering contacts together with links to LinkedIn profiles.
  • Display attendance at partnering conferences and increase networking opportunities.

"Pharma companies need new and innovative ways to share the financial risk of developing drugs," said Mark Gordon, director of product strategy at Thomson Reuters. "This new initiative benefits both drug innovators, who can easily update their partnering information online, as well as in-licensors, who can quickly find assets available for partnering."

"The Outpartnering Registry from Thomson Reuters will make it easier for us to market products for our clients," said Damon Bowe, consultant at New Orleans BioInnovation Center. "The industry has expressed the need for this registry and it is an effective way for us to market inventions and to create partnerships between academia and industry."

For more information about The Outpartnering Registry, please visit: http://go.thomsonreuters.com/outpartnering
For more information about Thomson Pharma Partnering, please visit: http://go.thomsonreuters.com/partnering

More News:

All news »

What are your comments?

Join the discussion today. Login Here.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments